Cell Signaling Technology Logo - Extra Large
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FMC63 scFv (F2Q8G) Rabbit Monoclonal Antibody (PE Conjugate) #87980

Filter:
  • F

    Product Specifications

    REACTIVITY All
    SENSITIVITY Transfected Only
    MW (kDa)
    Source/Isotype Rabbit IgG
    Application Key:
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • All-All Species Expected 

    Product Information

    Product Description

    This Cell Signaling Technology® antibody is conjugated to phycoerythrin (PE) under optimal conditions. This antibody conjugate is expected to exhibit the same species cross-reactivity as the unconjugated FMC63 scFv (F2Q8G) Rabbit Monoclonal Antibody #16563.

    Fluorescent Properties

    • ← Excitation: 565 nm ← Emission: 575 nm

    Product Usage Information

    Application Dilution
    Flow Cytometry (Fixed/Permeabilized) 1:800
    Flow Cytometry (Live) 1:50

    Storage

    Supplied in PBS (pH 7.2), less than 0.1% sodium azide, and 2 mg/mL BSA. Store at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.

    Protocol

    Specificity / Sensitivity

    FMC63 scFv (F2Q8G) Rabbit Monoclonal Antibody (PE Conjugate) recognizes exogenously expressed levels of CARs containing an FMC63-derived scFv.

    Species Reactivity:

    All Species Expected

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with an scFv derived from a murine Anti-CD19 monoclonal antibody, FMC63.

    Background

    Chimeric antigen receptor (CAR) T cell therapy utilizes synthetic receptors to redirect T cells to bind and eliminate tumor cells, bypassing traditional T cell receptor (TCR) signaling (1). The extracellular domain of conventional CARs consists of single-chain variable fragments (scFvs), which recognize and bind target antigens (1). CARs engineered to express the scFv of a murine Anti-CD19 antibody, FMC63, have shown clinical success in targeting CD19-expressing malignant B cells for degradation. This clinical success has led to several FMC63-based CARs being approved by the U.S. Food and Drug Administration (FDA) for the treatment of B-cell leukemia and lymphoma (2,3).

    Alternate Names

    B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; B4; CD19; CD19 antigen; CD19 molecule; CVID3; Differentiation antigen CD19; MGC12802; T-cell surface antigen Leu-12

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.